Realising the Therapeutic Potential of Neuroactive Steroid Modulators of the GABAA Receptor Belelli, Delia; Hogenkamp, Derk; Gee, Kelvin W.; Lambert, Jeremy J
Total Page：16
File Type：pdf, Size：1020Kb
University of Dundee Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor Belelli, Delia; Hogenkamp, Derk; Gee, Kelvin W.; Lambert, Jeremy J. Published in: Neurobiology of Stress DOI: 10.1016/j.ynstr.2019.100207 Publication date: 2020 Licence: CC BY-NC-ND Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Belelli, D., Hogenkamp, D., Gee, K. W., & Lambert, J. J. (2020). Realising the therapeutic potential of neuroactive steroid modulators of the GABA receptor. Neurobiology of Stress, 12, 1-11. [100207]. https://doi.org/10.1016/j.ynstr.2019.100207 A General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 24. Sep. 2021 Neurobiology of Stress 12 (2020) 100207 Contents lists available at ScienceDirect Neurobiology of Stress journal homepage: www.elsevier.com/locate/ynstr Realising the therapeutic potential of neuroactive steroid modulators of the T GABAA receptor ∗ Delia Belellia, Derk Hogenkampb, Kelvin W. Geeb, Jeremy J. Lamberta, a Systems Medicine, Neuroscience, Mail Box 6, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, United Kingdom b Department of Pharmacology, 110C Med Surge1, Mail Code 4625, University of California, Irvine, School of Medicine, Irvine, CA, 92697, USA ARTICLE INFO ABSTRACT Keywords: In the 1980s particular endogenous metabolites of progesterone and of deoxycorticosterone were revealed to be Allopregnanolone potent, efficacious, positive allosteric modulators (PAMs) of the GABAA receptor (GABAAR). These reports were GABAA receptor followed by the discovery that such steroids may be synthesised not only in peripheral endocrine glands, but Neurosteroid locally in the central nervous system (CNS), to potentially act as paracrine, or autocrine “neurosteroid” mes- Phasic inhibition sengers, thereby fine tuning neuronal inhibition. These discoveries triggered enthusiasm to elucidate the phy- Tonic inhibition siological role of such neurosteroids and explore whether their levels may be perturbed in particular psychiatric and neurological disorders. In preclinical studies the GABAAR-active steroids were shown to exhibit anxiolytic, anticonvulsant, analgesic and sedative properties and at relatively high doses to induce a state of general an- aesthesia. Collectively, these findings encouraged efforts to investigate the therapeutic potential of neurosteroids and related synthetic analogues. However, following over 30 years of investigation, realising their possible medical potential has proved challenging. The recent FDA approval for the natural neurosteroid allopregna- nolone (brexanolone) to treat postpartum depression (PPD) should trigger renewed enthusiasm for neurosteroid research. Here we focus on the influence of neuroactive steroids on GABA-ergic signalling and on the challenges faced in developing such steroids as anaesthetics, sedatives, analgesics, anticonvulsants, antidepressants and as treatments for neurodegenerative disorders. 1. Introduction mammalian central nervous system (CNS), the GABAAR, may be subject to physiological, or pathophysiological regulation (Harrison and Almost 80 years ago Hans Selye demonstrated that particular Simmonds, 1984). In confirmation, subsequent electrophysiological pregnane steroids can induce rapid sedation and a state of un- and radioligand binding approaches revealed particular metabolites of consciousness (Selye, 1941). Approximately 40 years elapsed before a progesterone (e.g., 5α-pregnan-3α-ol-20-one, also known as allo- viable molecular mechanism emerged to explain these rapid beha- pregnanolone and now brexanolone) and of deoxycorticosterone (5α- vioural effects. Electrophysiological studies revealed the intravenous pregnan-3α, 21-diol-20-one, [5α-THDOC]) to also be highly efficacious, synthetic steroidal general anesthetic alphaxalone (5α-pregnane-3α-ol- stereoselective, positive allosteric modulators (PAMs) of the GABAARat 11, 20-dione) to enhance the inhibitory effects of GABA in guinea pig nM concentrations (Majewska et al., 1986; Barker et al., 1987; olfactory cortex (Scholfield, 1980) and in cat spinal cord neurons Callachan et al., 1987; Cottrell et al., 1987; Gee et al., 1988; Peters (Lodge and Anis, 1984). Extracellular recordings in the rat cuneate et al., 1988). Radioligand binding and electrophysiological studies es- nucleus demonstrated alphaxalone to potently enhance responses tablished that the GABA facilitatory actions of these steroids were not mediated by GABAA receptor (GABAAR) agonists (Harrison and mediated by binding to the proposed benzodiazepine site on the GA- Simmonds, 1984). Supporting the GABAAR as a locus for the beha- BAAR(Harrison and Simmonds, 1984; Cottrell et al., 1987; Gee et al., vioural effect, betaxalone, a 3β-ol isomer of alphaxalone, had no effect 1988). In common with barbiturates, these steroids promoted the open on GABAARs and was behaviourally inert (Harrison and Simmonds, conducting state of the GABAAR associated anion channel, thereby 1984). In their seminal paper they recalled that alphaxalone was enhancing the actions of GABA and at higher concentrations, they di- structurally related to certain endogenous pregnane steroids, raising the rectly activated the receptor (Majewska et al., 1986; Barker et al., 1987; prospect that the activity of the major inhibitory receptor in the Callachan et al., 1987; Cottrell et al., 1987; Peters et al., 1988), leading ∗ Corresponding author. E-mail address: [email protected] (J.J. Lambert). https://doi.org/10.1016/j.ynstr.2019.100207 Received 21 November 2019; Accepted 19 December 2019 Available online 23 December 2019 2352-2895/ © 2019 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). D. Belelli, et al. Neurobiology of Stress 12 (2020) 100207 Abbreviations nRT nucleus reticularis NREM non rapid eye movement Ad Alzheimer's disease ORG ORG OD02-0 allopregnanolone 5α-pregnan-3α-ol-20-one PAM positive allosteric modulator CNS central nervous system PD pharmacodynamic DGGCs dentate gyrus granule cells pGPCR progesterone G-protein coupled receptor EEG electroencephalogram PK pharmacokinetic FDA food and drug administration PKA protein kinase A GABAAR GABAA receptor PKC protein kinase C HPA hypothalamus, pituitary, adrenal axis po oral administration IPSC inhibitory postsynaptic current PPD postpartum depression im intramuscular REM rapid eye movement iv intravenous SE status epilepticus MOA mechanism of action VB ventrobasal to their description as “barbiturate-like” modulators (Harrison and GABAARs. In agreement with previous studies (Belelli et al., 2009 Simmonds, 1984 Majewska et al., 1986), although subsequently bar- Brickley and Mody, 2012) inspection of Table 1 reveals little GABAAR biturate/steroid interaction studies implied these GABAAR modulators isoform specificity of these steroids. Given this GABAAR promiscuity a acted via distinct sites (Cottrell et al., 1987; Gee et al., 1988; Peters key question concerns the identification of the GABAAR subtypes that et al., 1988). The potency and stereoselectivity of their actions sug- mediate the behavioural repertoire neurosteroids. Experiments with gested involvement of a high affinity steroid binding site located on the “knock-in” mice genetically engineered to express diazepam-insensitive GABAAR. However, the apparent affinity derived from functional stu- and etomidate-insensitive GABAARs have revealed components of their dies may be misleading as these steroids are highly lipophilic, causing behavioural effects to be mediated by particular GABAARs (Rudolph their accumulation to relatively high local concentrations in the and Knoflach, 2011). Key transmembrane amino acids have been membrane i.e. in close apposition to a proposed transmembrane binding identified that impair neurosteroid modulation of GABAARs, permitting site for the steroid on the GABAAR protein (Hosie et al., 2006; Chisari equivalent mouse behavioural studies, although to date there has not et al., 2010). been a comprehensive behavioural profile of such mice (Newman et al., In this review we use the term neurosteroid for endogenous steroids 2016). In the absence of such studies, components of the behavioural synthesised in the CNS and the term neuroactive steroid for exogenous effects neuroactive steroids may exhibit a similar receptor profile to GABAAR-active steroids. those of other GABAAR modulators. However, whereas the effects of diazepam are mediated by enhancing the effects of GABA at γ-GA- BAARs, importantly neurosteroids additionally act as PAMs of δ-GA- 2. Neuroactive steroids and GABAAR subtypes BAARs. Indeed, behavioural studies of mice with deletion